• 1
    Barri YM , SanchezEQ, JenningsLW, et al. Acute kidney injury following liver transplantation: definition and outcome. Liver Transpl 2009; 15: 47583.
  • 2
    Gonwa TA , MaiML, MeltonLB, et al. Renal replacement therapy and orthotopic liver transplantation: the role of continuous veno-venous hemodialysis. Transplantation 2001; 71: 14248.
  • 3
    Afonso RC , HidalgoR, ZurstrassenMP, et al. Impact of renal failure on liver transplantation survival. Transplant Proc2008; 40: 80810.
  • 4
    Ziolkowski J , PaczekL, SenatorskiG, et al. Renal function after liver transplantation: calcineurin inhibitor nephrotoxicity. Transplant Proc 2003; 35: 23079.
  • 5
    Gonwa TA , MaiML, MeltonLB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001; 72: 19349.
  • 6
    Trawale JM , ParadisV, RautouPE, et al. The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study. Liver Int 2010; 30: 72532.
  • 7
    Saner F , KavukI, LangH, et al. Terlipressin and gelafundin: safe therapy of hepatorenal syndrome. Eur J Med Res 2004; 9: 7882.
  • 8
    Salerno F , GerbesA, GinesP, WongF, ArroyoV.Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut2007; 56: 13108.
  • 9
    Gines P , GuevaraM, ArroyoV, RodesJ.Hepatorenal syndrome. Lancet2003; 362: 181927.
  • 10
    Guevara M , GinesP, Fernandez-EsparrachG, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology1998; 27: 3541.
  • 11
    Uriz J , GinesP, CardenasA, et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 438.
  • 12
    Martin-Llahi M , PepinMN, GuevaraM, et al. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology 2008; 134: 13529.
  • 13
    Sanyal AJ , BoyerT, Garcia-TsaoG, et al. A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology2008; 134: 13608.
  • 14
    Mukhtar A , SalahM, AboulfetouhF, et al. The use of terlipressin during living donor liver transplantation: effects on systemic and splanchnic hemodynamics and renal function. Crit Care Med 2011; 10: 94100.
  • 15
    Mehta RL , ChertowGM.Acute renal failure definitions and classification: time for change? J Am Soc Nephrol 2003; 14: 217887.
  • 16
    Bellomo R , RoncoC, KellumJA, MehtaRL, PalevskyP.Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R2042.
  • 17
    Mehta RL , KellumJA, ShahSV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R318.
  • 18
    Kuwabara T , MoriK, MukoyamaM, et al. Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int2009; 75: 28594.
  • 19
    Niemann CU , WaliaA, WaldmanJ, et al. Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-associated lipocalin. Liver Transpl2009; 15: 185260.
  • 20
    Wagener G , MinhazM, MattisFA, et al. Urinary neutrophil gelatinase-associated lipocalin as a marker of acute kidney injury after orthotopic liver transplantation. Nephrol Dial Transplant2011; 26657: 171723.
  • 21
    Parikh CR , SandmaierBM, StorbRF, et al. Acute renal failure after nonmyeloablative hematopoietic cell transplantation. J Am Soc Nephrol2004; 15: 186876.
  • 22
    Parikh CR , JaniA, MishraJ, et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant2006; 6: 163945.
  • 23
    Ichimura T , BonventreJV, BaillyV, et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem1998; 273: 413542.
  • 24
    Han WK , WagenerG, ZhuY, WangS, LeeHT.Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol2009; 4: 87382.
  • 25
    Grubb AO. Cystatin C – properties and use as diagnostic marker. Adv Clin Chem2000; 35: 6399.
  • 26
    Herget-Rosenthal S , MarggrafG, HusingJ, et al. Early detection of acute renal failure by serum cystatin C. Kidney Int2004; 66: 111522.
  • 27
    Nishiyama A , MajidDS, WalkerMIII, MiyatakeA, NavarLG.Renal interstitial atp responses to changes in arterial pressure during alterations in tubuloglomerular feedback activity. Hypertension2001; 37: 7539.
  • 28
    Majid DS , SaidKE, OmoroSA, NavarLG.Nitric oxide dependency of arterial pressure-induced changes in renal interstitial hydrostatic pressure in dogs. Circ Res2001; 88: 34751.
  • 29
    Persson PB , EhmkeH, KirchheimHR, et al. Autoregulation and non-homeostatic behaviour of renal blood flow in conscious dogs. J Physiol1993; 462: 26173.
  • 30
    Stocker SD , SvedAF, StrickerEM.Role of renin-angiotensin system in hypotension-evoked thirst: studies with hydralazine. Am J Physiol Regul Integr Comp Physiol 2000; 279: R57685.
  • 31
    Kelleher SP , RobinetteJB, CongerJD.Sympathetic nervous system in the loss of autoregulation in acute renal failure. Am J Physiol1984; 246: F37986.
  • 32
    Biancofiore G , BindiML, RomanelliAM, et al. Postoperative intra-abdominal pressure and renal function after liver transplantation. Arch Surg2003; 138: 7036.
  • 33
    Dalfino L , TulloL, DonadioI, MalcangiV, BrienzaN.Intra-abdominal hypertension and acute renal failure in critically ill patients. Intensive Care Med2008; 34: 70713.
  • 34
    Mangano CM , DiamondstoneLS, RamsayJG, et al. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Ann Intern Med 1998; 128: 194203.
  • 35
    Wang C , LouTQ, TangH, et al. Clearance effect of different blood purification techniques on parathyroid hormone in renal function failure patients on maintenance hemodialysis. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue2004; 16: 7535.
  • 36
    Cabezuelo JB , RamirezP, RiosA, et al. Risk factors of acute renal failure after liver transplantation. Kidney Int2006; 69: 107380.
  • 37
    Solomon R , WernerC, MannD, D'EliaJ, SilvaP.Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med1994; 331: 141620.
  • 38
    Belani KG , PalahniukRJ.Kidney transplantation. Int Anesthesiol Clin1991; 29: 1739.
  • 39
    Wilkes NJ , WoolfR, MutchM, et al. The effects of balanced versus saline-based hetastarch and crystalloid solutions on acid-base and electrolyte status and gastric mucosal perfusion in elderly surgical patients. Anesth Analg2001; 93: 8116.
  • 40
    O'Malley CM , FrumentoRJ, HardyMA, et al. A randomized, double-blind comparison of lactated Ringer's solution and 0.9% NaCl during renal transplantation. Anesth Analg2005; 100: 151824.
  • 41
    Bourgoin A , LeoneM, DelmasA, et al. Increasing mean arterial pressure in patients with septic shock: effects on oxygen variables and renal function. Crit Care Med 2005; 33: 7806.
  • 42
    Osthaus WA , HuberD, BaumkerC, et al. Plasma volume replacement with HES 130/0.42 obviates negative side effects of pneumoperitoneum in piglets. Paediatr Anaesth2008; 18: 9228.
  • 43
    Brunkhorst FM , EngelC, BloosF, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med2008; 358: 12539.
  • 44
    Mukhtar A , AboulfetouhF, ObayahG, et al. The safety of modern hydroxyethyl starch in living donor liver transplantation: a comparison with human albumin. Anesth Analg 2009; 109: 92430.
  • 45
    Payen D , de PontAC, SakrY, et al. A positive fluid balance is associated with a worse outcome in patients with acute renal failure. Crit Care2008; 12: R7480.
  • 46
    Bouchard J , SorokoSB, ChertowGM, et al. Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int2009; 76: 4227.
  • 47
    Foland JA , FortenberryJD, WarshawBL, et al. Fluid overload before continuous hemofiltration and survival in critically ill children: a retrospective analysis. Crit Care Med 2004; 32: 17716.
  • 48
    Gillespie RS , SeidelK, SymonsJM.Effect of fluid overload and dose of replacement fluid on survival in hemofiltration. Pediatr Nephrol2004; 19: 13949.
  • 49
    Goldstein SL. Hemodialysis in the pediatric patient: state of the art. Adv Ren Replace Ther 2001; 8: 1739.
  • 50
    Hayes GR , WilliamsA, CostelloCE, EnnsCA, LucasJJ.The critical glycosylation site of human transferrin receptor contains a high-mannose oligosaccharide. Glycobiology1995; 5: 22732.
  • 51
    Ho KM , SheridanDJ.Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ2006; 333: 420.
  • 52
    Kellum JA. Diuretics in acute renal failure: protective or deleterious. Blood Purif 1997; 15: 31922.
  • 53
    McDonald RH Jr , GoldbergLI, McNayJL, TuttleEPJrEffect of dopamine in man: augmentation of sodium excretion, glomerular filtration rate, and renal plasma flow. J Clin Invest 1964; 43: 111624.
  • 54
    Kellum JA , DeckerM.Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001; 29: 152631.
  • 55
    Bellomo R , ChapmanM, FinferS, HicklingK, MyburghJ.Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000; 356: 213943.
  • 56
    De Backer D , BistonP, DevriendtJ, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med2010; 362: 77989.
  • 57
    Halpenny M , RusheC, BreenP, et al. The effects of fenoldopam on renal function in patients undergoing elective aortic surgery. Eur J Anaesthesiol2002; 19: 329.
  • 58
    Stone GW , McCulloughPA, TumlinJA, et al. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. JAMA 2003; 290: 228491.
  • 59
    Morelli A , RicciZ, BellomoR, et al. Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial. Crit Care Med 2005; 33: 24516.
  • 60
    Ojo AO , HeldPJ, PortFK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med2003; 349: 93140.
  • 61
    Sharma P , WelchK, EikstadtR, et al. Renal outcomes after liver transplantation in the model for end-stage liver disease era. Liver Transpl2009; 15: 11428.
  • 62
    Gonwa TA , McBrideMA, AndersonK, et al. Continued influence of preoperative renal function on outcome of orthotopic liver transplant (OLTX) in the US: where will MELD lead us? Am J Transplant 2006; 6: 26519.
  • 63
    Bahirwani R , ReddyKR.Outcomes after liver transplantation: chronic kidney disease. Liver Transpl 2009; 15(Suppl. 2): S704.
  • 64
    Farkas SA , SchnitzbauerAA, KirchnerG, et al. Calcineurin inhibitor minimization protocols in liver transplantation. Transpl Int2009; 22: 4960.
  • 65
    Kornberg A , KupperB, HommannM, ScheeleJ.Introduction of MMF in conjunction with stepwise reduction of calcineurin inhibitor in stable liver transplant patients with renal dysfunction. Int Immunopharmacol2005; 5: 1416.
  • 66
    Cicinnati VR , YuZ, KleinCG, et al. Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients – assessment of renal and allograft function, cardiovascular risk factors and immune monitoring. Aliment Pharmacol Ther 2007; 26: 1195208.
  • 67
    Biselli M , VitaleG, GramenziA, et al. Two yr mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant. Clin Transplant2009; 23: 1918.
  • 68
    Nishibayashi S , HattoriK, HiranoT, et al. Functional and structural changes in end-stage kidney disease due to glomerulonephritis induced by the recombinant alpha3(IV)NC1 domain. Exp Anim2010; 59: 15770.
  • 69
    Tapia E , FrancoM, Sanchez-LozadaLG, et al. Mycophenolate mofetil prevents arteriolopathy and renal injury in subtotal ablation despite persistent hypertension. Kidney Int2003; 63: 9941002.
  • 70
    Allison AC , EuguiEM.Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation2005; 80: S18190.
  • 71
    Shipkova M , ArmstrongVW, OellerichM, WielandE.Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. Expert Opin Drug Metab Toxicol 2005; 1: 50526.
  • 72
    Brunet M , CireraI, MartorellJ, et al. Sequential determination of pharmacokinetics and pharmacodynamics of mycophenolic acid in liver transplant patients treated with mycophenolate mofetil. Transplantation2006; 81: 5416.
  • 73
    Robaeys G , CassimanD, VerslypeC, et al. Successful conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic) in liver transplant patients with gastrointestinal side effects. Transplant Proc2009; 41: 6103.
  • 74
    Pietruck F , bbud-FilhoM, VathsalaA, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable maintenance renal transplant patients: pooled results from three international, multicenter studies. Transplant Proc 2007; 39: 1038.
  • 75
    Nashan B , IvensK, SuwelackB, ArnsW, AbbudFM.Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: preliminary results from the myfortic prospective multicenter study. Transplant Proc 2004; 36: 521S3S.
  • 76
    Budde K , CurtisJ, KnollG, et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant 2004; 4: 23743.
  • 77
    Cooper M , DeeringKL, SlakeyDP, et al. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients. Transplantation2009; 88: 51420.
  • 78
    Pageaux GP , RostaingL, CalmusY, et al. Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Liver Transpl2006; 12: 175560.
  • 79
    Kornberg A , KupperB, ThrumK, et al. Sustained Renal Response to Mycophenolate Mofetil and CNI Taper Promotes Survival in Liver Transplant Patients with CNI-Related Renal Dysfunction. Dig Dis Sci2010; 56: 24451.
  • 80
    Neuberger JM , MamelokRD, NeuhausP, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the ‘ReSpECT’ study. Am J Transplant 2009; 9: 32736.
  • 81
    Yoshida EM , MarottaPJ, GreigPD, et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 2005; 11: 106472.
  • 82
    Bajjoka I , HsaikyL, BrownK, AbouljoudM.Preserving renal function in liver transplant recipients with rabbit anti-thymocyte globulin and delayed initiation of calcineurin inhibitors. Liver Transpl2008; 14: 6672.
  • 83
    Soliman T , HetzH, BurghuberC, et al. Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl2007; 13: 103944.
  • 84
    Dharancy S , IannelliA, HulinA, et al. Mycophenolate mofetil monotherapy for severe side effects of calcineurin inhibitors following liver transplantation. Am J Transplant2009; 9: 6103.
  • 85
    Moreno Planas JM , Cuervas-MonsMV, RubioGE, et al. Mycophenolate mofetil can be used as monotherapy late after liver transplantation. Am J Transplant2004; 4: 16505.
  • 86
    Fairbanks KD , ThuluvathPJ.Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience. Liver Transpl 2004; 10: 118994.
  • 87
    Ko HH , GreanyaE, LeeTK, et al. Mycophenolate mofetil in liver transplant patients with calcineurin-inhibitor-induced renal impairment. Ann Hepatol2008; 7: 37680.
  • 88
    Manrique A , JimenezC, OrtegaP, et al. Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis. Transplant Proc2008; 40: 29624.
  • 89
    Schlitt HJ , BarkmannA, BokerKH, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001; 357: 58791.
  • 90
    Wood KJ , SakaguchiS.Regulatory T cells in transplantation tolerance. Nat Rev Immunol2003; 3: 199210.
  • 91
    Zeiser R , NguyenVH, BeilhackA, et al. Inhibition of CD4+CD25+regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood2006; 108: 3909.
  • 92
    Demirkiran A , SewgobindVD, van derWJ, et al. Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4+FOXP3+regulatory T cells. Transplantation2009; 87: 10628.
  • 93
    DuBay D , SmithRJ, QiuKG, et al. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens. Liver Transpl2008; 14: 6519.
  • 94
    Harper SJ , GelsonW, HarperIG, AlexanderGJ, GibbsP.Switching to sirolimus-based immune suppression after liver transplantation is safe and effective: A single-center experience. Transplantation 2010; 91: 12832.
  • 95
    Watson CJ , GimsonAE, AlexanderGJ, et al. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl2007; 13: 1694702.
  • 96
    Shenoy S , HardingerKL, CrippinJ, et al. Sirolimus conversion in liver transplant recipients with renal dysfunction: a prospective, randomized, single-center trial. Transplantation 2007; 83: 138992.
  • 97
    Masetti M , MontaltiR, RompianesiG, et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant2010; 10: 225262.
  • 98
    Castroagudin JF , MolinaE, RomeroR, et al. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl2009; 15: 17927.
  • 99
    Schnitzbauer AA , SchererMN, RochonJ, et al. Study protocol: a pilot study to determine the safety and efficacy of induction-therapy, de novo MPA and delayed mTOR-inhibition in liver transplant recipients with impaired renal function. PATRON-study. BMC Nephrol 2010; 11: 2430.
  • 100
    Teperman L , SherL, MarottaP, et al. Efficacy of mycophenolate mofetil/sirolimus maintenance therapy after CNI withdrawal in liver transplant recipients: 1-year outcomes of the spare-the-nephron (STN) trial. Am J Transplant 2011; 9: 22930.
  • 101
    Cattaneo D , MerliniS, ZenoniS, et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant2005; 5: 293744.
  • 102
    Boillot O , SeketB, DumortierJ, et al. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study. Liver Transpl 2009; 15: 142634.